English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Fecha de publicación: Enero 2019Valproic acid promotes a decrease in mycobacterial survival by enhancing nitric oxide production in macrophages...
-
UDIBI
Published: September 20, 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract...
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. SHOW MORE
-
UDIBI
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. SHOW MORE
-
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
